MGM-16: Complete Evidence, Opioid Pharmacology, Dependence & Safety Monograph

MGM-16: What It Is, Opioid Pharmacology, Risks & Schedule I Status

Emergency opioid safety: MGM-16 is a potent opioid-receptor agonist in preclinical systems with no established safe human dose. If someone cannot be awakened, has slow/irregular/stopped breathing, blue or gray lips/skin, gurgling/choking, or severe collapse after a suspected kratom-derived or unknown opioid product, call emergency services. Naloxone is appropriate when opioid exposure is possible, although no controlled MGM-16-specific human reversal study exists and emergency care remains necessary.

MGM-16 has no FDA-approved medical use and is currently a U.S. Schedule I controlled substance. This page does not provide dosing, sourcing, synthesis, administration optimization, or self-directed withdrawal instructions.

Quick answer

MGM-16 is a laboratory-developed, fluorinated derivative in the 7-hydroxymitragynine chemical family. It was created during medicinal-chemistry research as a close analogue of MGM-15 and was studied as a dual mu-opioid receptor (MOR) and delta-opioid receptor (DOR) agonist.

The scientific evidence is unusually lopsided: MGM-16 has striking preclinical pharmacology but almost no clinically useful human evidence. The best-known study was published in 2014 and reported high opioid-receptor affinity plus very potent antinociceptive effects in mice. Those animal results do not establish a human dose, human potency ratio, safety margin, therapeutic benefit, or overdose threshold.

As of October 2026, MGM-16 is also federally controlled in the United States. DEA's temporary scheduling order placed MGM-16, MGM-15, and mitragynine pseudoindoxyl in Schedule I effective August 26, 2026, with the order currently running through August 26, 2028 unless extended or replaced through the permanent scheduling process.

Evidence grade for human effects: Very Low.

Identity card and naming

Naming matters because regulatory summaries and chemical suppliers have not always used identical corynanthe numbering. The safest way to resolve ambiguity is the structure plus CAS number, not a position number alone.

History: from medicinal chemistry to anticipatory scheduling

MGM-16 was first described in the peer-reviewed literature in 2014 during medicinal-chemistry work exploring 7-hydroxymitragynine derivatives for analgesic activity. The compound showed unusually strong mu/delta opioid pharmacology in laboratory and mouse models.

Unlike MGM-15 and mitragynine pseudoindoxyl, MGM-16 did not have a comparable documented consumer-market or overdose case series in DEA's 2026 record. DEA nevertheless temporarily scheduled it because of its potent opioid pharmacology, close structural relationship to compounds already entering the market, and concern that it could emerge as a substitute.

That history makes MGM-16 a useful example of hazard evidence arriving before epidemiology: the pharmacology is strong enough to justify concern, while the human exposure record remains extremely sparse.

What is MGM-16?

MGM-16 is a semi-synthetic 7-hydroxymitragynine-derived research compound. It is closely related to MGM-15, also called dihydro-7-hydroxymitragynine, but MGM-16 adds a fluorine substitution to that chemical scaffold.

That makes it very different from traditional kratom leaf. Kratom (Mitragyna speciosa) naturally contains a mixture of alkaloids dominated by mitragynine. MGM-16 was deliberately created through chemical modification for pharmacology research; it should not be described as a normal kratom constituent.

Why did researchers create it?

The original medicinal-chemistry work was trying to explore whether derivatives of 7-hydroxymitragynine could produce useful activity in acute and neuropathic pain models.

In the 2014 study, researchers tested both MGM-15 and MGM-16. MGM-16 showed strong binding to mu- and delta-opioid receptors and acted as a full agonist in the laboratory assays used in that paper. The same study then tested the compound in mouse models of acute pain and neuropathic allodynia.

This is the foundation for most modern claims about MGM-16.

It is also the reason those claims need context: the evidence base is largely one preclinical pharmacology program, not a sequence of human clinical trials.

Opioid pharmacology: what the 2014 study actually found

The main study reported high affinity for both mu- and delta-opioid receptors, with reported binding values of approximately:

• MOR Ki: 2.1 nM
• DOR Ki: 7.0 nM

MGM-16 also showed agonist activity in GTP-gamma-S signaling assays and in isolated-tissue functional tests. In mice, systemic administration produced antinociceptive effects in an acute pain model and antiallodynic effects in a partial sciatic-nerve ligation model.

Those results support a straightforward conclusion: MGM-16 is a potent opioid-receptor agonist in the experimental systems that have been studied.

They do not support several stronger conclusions that are sometimes attached to the compound online.

Is MGM-16 really “240 times stronger than morphine”?

This is the number most likely to be misunderstood.

The 2014 paper reported that MGM-16's antinociceptive effect was approximately 240 times more potent than morphine in a mouse tail-flick test. That is a real result from the study, but it is not a validated human potency ratio.

A mouse tail-flick assay measures a specific experimental pain response under a specific protocol. The ratio can be affected by species, administration route, metabolism, receptor pharmacology, measured endpoint, and timing.

So the careful interpretation is:

MGM-16 produced very potent antinociception in one mouse assay, where the reported dose-potency comparison was roughly 240-fold versus morphine.

It is not accurate to turn that into “MGM-16 is 240 times stronger than morphine in people.”

That distinction matters for safety. Converting an animal potency ratio into a human dose estimate would be scientifically unsupported and potentially dangerous.

What about the “100 times gabapentin” claim?

The same study reported that MGM-16 was approximately 100 times more potent than gabapentin in a partial sciatic nerve-ligation mouse model of neuropathic allodynia.

Again, this is an assay-specific animal comparison, not evidence that MGM-16 is clinically superior to gabapentin or that a particular human dose can be inferred.

No randomized human trial has shown that MGM-16 treats neuropathic pain.

Pharmacokinetics and metabolism: not established in humans

No controlled human MGM-16 study has established:

• absorption or oral bioavailability;
• time to peak concentration;
• distribution;
• human half-life;
• CYP or UGT pathways;
• active metabolites;
• renal or hepatic clearance;
• accumulation with repeated exposure;
• exposure-response relationships.

The 2014 animal paper supports oral activity in mice but does not supply human pharmacokinetics.

This is an important evidence boundary. A chemically related compound's half-life cannot be copied onto MGM-16, and forum reports cannot substitute for measured human PK.

Human evidence hierarchy

Controlled human evidence

None identified.

Emergency-department / poison-center evidence

No MGM-16-specific clinical series identified in the sources used for this monograph.

Forensic toxicology and deaths

DEA's 2026 record discusses fatal toxicology involving MGM-15 and mitragynine pseudoindoxyl, while distinguishing MGM-16 as a pharmacologically concerning related substance without the same established human-market evidence. That absence must not be rewritten into a human fatality count for MGM-16.

Preclinical evidence

This is the dominant evidence layer: receptor binding/function, isolated-tissue assays, and mouse acute/neuropathic pain models.

Has MGM-16 been studied in humans?

No controlled human clinical evidence has established MGM-16's:

• pharmacokinetics;
• oral bioavailability in people;
• therapeutic dose range;
• respiratory-depression threshold;
• overdose threshold;
• interaction profile;
• dependence liability;
• withdrawal time course;
• long-term toxicity;
• efficacy for pain or any other condition.

That absence is especially important because opioid-receptor agonists can have steep dose-response curves and can become substantially more dangerous when combined with other central nervous system depressants.

Very Low evidence does not mean low risk. In this case it means a potent pharmacology signal exists while the human safety data needed to define the risk are missing.

Safety risks and interactions

Because MGM-16 acts as a potent opioid agonist in preclinical systems, the major safety concerns are the ones expected for powerful opioid-receptor activation:

• respiratory depression;
• profound sedation;
• impaired coordination and driving;
• loss of consciousness;
• physical dependence;
• withdrawal;
• overdose;
• elevated risk when combined with other sedating or respiratory-depressant drugs.

There are no controlled interaction studies that quantify MGM-16 risk with alcohol, benzodiazepines, prescription opioids, gabapentinoids, sedating antihistamines, sleep medications, or other depressants.

That means a lack of an MGM-16-specific interaction study should not be read as evidence that combinations are safe.

Emergency context: When opioid toxicity is suspected, naloxone may be relevant because it can reverse opioid effects, but emergency services are still necessary. A person can become sedated again after naloxone wears off, and an unverified product may contain more than one active drug.

Was MGM-16 actually sold in consumer products?

This is one area where MGM-16 differs from MGM-15.

In its August 2026 temporary scheduling order, DEA stated that it had evidence of mitragynine pseudoindoxyl and MGM-15 appearing in the Mitragyna speciosa consumer market, while it did not identify evidence that MGM-16 had already become established in that consumer market. The agency did note online indications that MGM-16 was being considered or advertised for future sale.

That distinction is worth preserving. MGM-16 was scheduled partly because of its pharmacology, close relationship to other emerging opioids, and perceived potential to enter the market—not because a large clinical or toxicology dataset already existed.

Tolerance, physical dependence, withdrawal, and addiction

What is directly known

There is no MGM-16-specific prospective human study of tolerance, physical dependence, withdrawal, craving, or substance use disorder.

What is biologically plausible

MGM-16 is a potent MOR/DOR agonist in preclinical systems. Repeated exposure to potent mu-opioid agonists can produce neuroadaptation, tolerance, physical dependence, and opioid-type withdrawal. That makes these outcomes biologically plausible and clinically concerning.

But class inference has limits. It cannot tell us:

• how rapidly MGM-16 tolerance develops in humans;
• the probability of dependence;
• withdrawal onset, peak, or duration;
• whether withdrawal is more or less severe than MGM-15, 7-OH, pseudoindoxyl, morphine, or another opioid;
• a valid self-taper schedule.

Physical dependence is not identical to addiction

Physical dependence means withdrawal occurs when drug exposure falls. Substance use disorder is a broader behavioral syndrome involving features such as craving, loss of control, repeated unsuccessful efforts to reduce use, continued use despite harm, hazardous use, or interference with responsibilities.

For MGM-16 specifically, there is not enough human evidence to estimate either syndrome's incidence.

Treatment and support

There is no MGM-16-specific treatment trial.

If a person presents after an unknown product with opioid intoxication, emergency care follows established opioid-overdose principles, including naloxone when opioid toxicity is suspected.

If repeated use has produced opioid-like withdrawal, craving, inability to stop, or continued use despite harm, clinicians can assess the person using established opioid use disorder frameworks. Evidence-based medications for OUD exist, but the absence of MGM-16 human PK makes internet-derived induction or taper schedules especially inappropriate.

U.S. readers seeking treatment can use FindTreatment.gov or SAMHSA's National Helpline at 1-800-662-HELP (4357).

Drug testing and toxicology

No routine immunoassay should be assumed to identify MGM-16 specifically.

A laboratory seeking MGM-16 would generally need a method that actually includes the compound—typically targeted or broad-spectrum LC-MS/MS or high-resolution mass spectrometry with appropriate reference material.

Important limits:

• a generic opioid screen can be negative even when an unconventional opioid is present;
• a kratom/mitragynine assay does not prove MGM-16 was tested;
• structural similarity to MGM-15/7-OH increases the importance of reference standards and chromatographic identification;
• a certificate of analysis only addresses the analytes, method, sample, and batch actually examined.

This is clinical/forensic interpretation, not test-evasion guidance.

Counterfeit, mislabeling, and market uncertainty

As of the 2026 federal scheduling record, MGM-16 had not been documented as established in the consumer market in the way MGM-15 and pseudoindoxyl had.

That means there is not a strong evidence base for claiming a characteristic MGM-16 tablet, brand, color, dosage form, or counterfeit pattern.

It also means a product labeled "MGM-16" should not be assumed authentic without analytical confirmation. The absence of published market evidence is not proof that every future or online-labeled product is fake; it is simply an evidence gap.

Forensic interpretation

Because MGM-16 lacks a substantial human toxicology series, several claims should be explicitly rejected:

• there is no validated fatal blood concentration;
• there is no human lethal dose;
• there is no postmortem concentration range that proves sole causation;
• there is no reliable prevalence estimate.

If MGM-16 is detected in a future clinical or death investigation, interpretation should consider specimen type, method specificity, co-drugs, tolerance, underlying disease, product composition, and the distinction between detection and causation.

Special populations

There are no adequate MGM-16-specific data for pregnancy, breastfeeding, adolescents, older adults, respiratory disease, seizure disorders, or significant hepatic/renal disease.

For a potent opioid-active compound with unknown human PK, those gaps warrant caution. They do not establish safety.

Myths and common misconceptions

"MGM-16 is 240 times morphine."
That compresses a mouse tail-flick assay into a human potency claim. The study does not establish a 240:1 human conversion.

"No human deaths means it is safer than MGM-15."
Not established. MGM-16 had much less documented human-market exposure when scheduled, so the evidence denominator is completely different.

"It's just fluorinated kratom."
Misleading. It is a laboratory-developed fluorinated analogue, not a normal kratom-leaf constituent.

"If it was orally active in mice, the human half-life and duration are known."
False. Oral activity is not a human PK study.

"Schedule I proves the exact danger level."
Schedule I is a legal classification. It does not quantify individual potency or overdose probability.

Evidence ledger

U.S. legal status in 2026

DEA's final temporary scheduling order became effective August 26, 2026 and placed these three substances in Schedule I:

• mitragynine pseudoindoxyl;
• MGM-15;
• MGM-16.

The order states that it is effective through August 26, 2028, unless extended or superseded by permanent scheduling action.

For the general public, Schedule I status means unauthorized manufacture, distribution, sale, or possession is subject to the Controlled Substances Act. Research handling also requires the appropriate DEA authorization.

This is separate from the regulatory treatment of ordinary kratom leaf and from the separate federal proceeding involving specified 7-hydroxymitragynine products. Chemical similarity does not make those legal categories interchangeable.

MGM-16 vs MGM-15 vs 7-OH

The most important point is that these compounds should not be treated as interchangeable. Similar chemical ancestry does not create identical pharmacokinetics, toxicity, product composition, or legal status.

Frequently asked questions

Is MGM-16 a kratom alkaloid?

Not in the usual sense. MGM-16 is a laboratory-developed derivative based on the 7-hydroxymitragynine chemical scaffold. It is not a normal constituent of traditional kratom leaf.

Is MGM-16 stronger than MGM-15?

The 2014 preclinical study reported greater potency for MGM-16 than MGM-15 in the assays it used. That does not establish a universal human potency ranking.

Is MGM-16 an opioid?

Its pharmacology is opioid-like in a very direct sense: the main study found high-affinity agonist activity at mu- and delta-opioid receptors and opioid-mediated effects in animal models.

Does MGM-16 have medical benefits?

Preclinical pain models produced interesting results, but no controlled human clinical trial has established MGM-16 as a safe or effective treatment.

Is MGM-16 legal to possess in the United States?

Unauthorized possession is prohibited under the current federal Schedule I temporary order, effective August 26, 2026.

Why did DEA schedule MGM-16 if it was not widely sold?

DEA cited MGM-16's potent opioid pharmacology, chemical relationship to emerging 7-OH-derived substances, and potential to appear as a substitute in the drug market. The order specifically distinguished that risk from established evidence of widespread MGM-16 consumer-market presence.

What the evidence does — and does not — justify

Supported:

• MGM-16 is a distinct synthetic/semi-synthetic derivative in the 7-OH/MGM-15 family.
• It has high-affinity mu- and delta-opioid receptor activity in preclinical assays.
• It produced potent antinociceptive and antiallodynic effects in mice.
• It is currently federally controlled in Schedule I in the United States.

Not established:

• a safe human dose;
• a human morphine-equivalent potency ratio;
• clinical efficacy for pain;
• a defined human half-life or pharmacokinetic profile;
• a quantified dependence or withdrawal timeline;
• a reliable overdose threshold;
• comparative human safety versus 7-OH, MGM-15, pseudoindoxyl, morphine, or other opioids.

Related evidence

• MGM-15 / Dihydro-7-hydroxymitragynine
• 7-Hydroxymitragynine evidence review
• Mitragynine pseudoindoxyl
• Mitragynine evidence review
• Substance Use, Dependence & Harm Reduction hub
• Kratom & 7-OH withdrawal: evidence and clinical context
• Novel psychoactive substances

Bottom line

MGM-16 is scientifically interesting because it shows very strong opioid pharmacology in preclinical models. That is also exactly why casual potency claims are risky.

The headline numbers—especially “240 times morphine”—come from animal experiments, not human clinical pharmacology. There is no validated human dose, no established medical use, and no controlled human safety program that turns those preclinical results into a usable clinical potency scale.

For current U.S. readers, there is also a clear legal update: MGM-16 has been in federal Schedule I since August 26, 2026.

Search methodology

This review prioritizes the original peer-reviewed MGM-16 pharmacology paper, subsequent peer-reviewed reviews, and primary U.S. federal regulatory sources. Human and animal evidence are separated explicitly. Potency ratios are reported only with the species and assay that produced them, and missing human data are treated as uncertainty rather than as evidence of safety.